Tencent and Johnson & Johnson Consumer Health China Launch Integrated Digital Platform 'Ai Bi E-Zhan' for Rhinitis Management

ShanghaiSeptember 1, 2022PR Newswire -- On August 30, the Allergic Disease Prevention and Control Public Education Conference Rhinitis Session, hosted by Tencent News and exclusively sponsored by Rhinocort, a nasal spray brand under Johnson & Johnson Personal Health Care, was successfully held in Shanghai. At the conference, Tencent and Johnson & Johnson Personal Health Care China jointly launched "iNose Station," a professional one-stop digital rhinitis management platform in the form of a mini program, providing comprehensive health management solutions for rhinitis patients ranging from prevention, diagnosis to treatment, helping to enhance disease awareness of rhinitis, promote standardized treatment and scientific medication concepts. Leading experts in the field of rhinitis, as well as leaders from Tencent and Johnson & Johnson Personal Health Care China, attended the event.

Allergic rhinitis is a very common disease. According to reports, the prevalence of allergic rhinitis in adults in China is about 17.6%.^[1], and the trend is increasing year by year. At the same time, the lack of awareness about the disease, incorrect self-diagnosis, and delayed treatment not only bring many troubles to patients' lives and work but also lead to a significant waste of medical and social resources.

Professor Sun Guangbin, Chief Physician at Huashan Hospital Affiliated with Fudan University, noted, "Pollen, animal dander, dust mites, fungi, air pollution, cold air, physical exercise, strong emotional reactions, tobacco smoke, alcoholic beverages, strong odors, and volatile organic compounds are 12 common triggers of rhinitis. From prevention to treatment and long-term management, allergic rhinitis requires continuous attention. If not promptly identified and treated in a standardized manner, it can severely impact life and social interactions, and may even develop into various diseases. Therefore, even if the symptoms are mild, patients with allergic rhinitis must adhere to standardized medication."

Professor Guangbin Sun, Chief Physician of Huashan Hospital Affiliated to Fudan University

"Nasal corticosteroids, which are the first-line recommendation in the rhinitis guidelines, can effectively combat various symptoms of rhinitis. Among them, budesonide has a wide range of applications. Its indications include allergic rhinitis, perennial non-allergic rhinitis, prevention of nasal polyp recurrence after polypectomy, and symptomatic treatment of nasal polyps. It has also been proven to effectively treat rhinitis caused or exacerbated by air pollution. Nasal corticosteroids are well-tolerated and a convenient choice for patients with rhinitis to manage their own health," shared Professor Hongfei Lou, Chief Physician at the Eye, Ear, Nose, and Throat Hospital of Fudan University.

Professor Hongfei Lou, Chief Physician of the Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University

To advance the digital innovation of rhinitis management and promote the integration of high-quality medical resources, Tencent and Johnson & Johnson China Personal Health Care have jointly launched the "iNose Station" mini-program, designed for the vast number of rhinitis patients. "iNose Station" isJohnson & Johnson China Personal Health CareThe first落地result after signing a strategic cooperation with Tencent this year, integrating six core functions, including self-assessment for rhinitis, rhinitis symptom rating, allergy index alerts, online medical consultation, one-click medication purchase, and educational content. Through one-stop scientific management, it provides end-to-end services addressing the needs of rhinitis patients throughout their entire disease journey.

From the left: Chen Xiaofeng, Head of Marketing at Johnson & Johnson China Personal Health Care; Conran Dae, President of Johnson & Johnson China Personal Health Care; Zhang Minyi, General Manager of Industry Sales Operations at Tencent Advertising; and Ye Shuozhi, Head of Pharmaceutical Industry at Tencent Advertising.

Declan Rooney, President of Johnson & Johnson China Personal Health Care, said: "We are delighted to witness the launch of the 'Love Nose e-Station' today. This is not only the first achievement implemented after Johnson & Johnson China Personal Health Care and Tencent formed a strategic partnership, but also provides new support for us to enhance the public's ability to manage their own health and help improve the health literacy of Chinese people. Rhinitis is a microcosm of many common diseases. We hope to leverage digital healthcare strategies to help patients and the public improve access to medical information and resources, further improving the prevention and treatment status of common diseases. We will continue to work tirelessly to improve people’s quality of life, reduce the burden on the healthcare system, and build a health ecosystem that involves multiple parties and benefits everyone."

Zhang Minyi, General Manager of Sales Operations at Tencent Advertising Industry, stated: "The launch of 'iNose e-Station' marks the first collaborative exploration between Tencent and Johnson & Johnson's Consumer Health division in China within the digital healthcare field. Moving forward, Tencent will continue to leverage its strengths and experience in traffic resources, private domain operational systems, and digital capabilities to accelerate the digital transformation of rhinitis disease management, providing a better healthcare experience for patients suffering from rhinitis."

Zhang Yu, Vice President of Tencent Health, expressed via live video connection, "iNose e-Station will provide a more efficient and convenient health management platform for patients with rhinitis by enhancing patient awareness of the disease, scientifically evaluating the condition, offering proper treatment advice, and ensuring standardized and rational medication. At the same time, relying on Tencent's user insights and connectivity advantages, we will integrate consultation, diagnosis, treatment, medication, and other health service components to build a one-stop medical service management platform, improving the standardized management level throughout the patient’s entire cycle. We believe that through the joint efforts of both parties, we can offer patients more valuable self-health management services."。"

In the future, the two parties will leverage their respective strengths to jointly explore multiple areas such as disease education, product development, content co-creation, and digital innovation. Driven by technology, they aim to accelerate the construction and transformation of digital capabilities in the personal health care sector, enhance user experience, and help more Chinese patients with rhinitis and consumers enjoy a health management lifestyle in the "Internet + medical" era, contributing to the early realization of the "Healthy China 2030" vision.

References:
1. Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in China (2022, Revised Edition)